One To Watch

Orexo

A Swedish specialty pharmaceutical company focused on drug delivery technologies and treatments for substance use disorders, mental health conditions and emergency medicines. Orexo combines proprietary formulation platforms with established active pharmaceutical ingredients to develop improved medicines and rescue therapies.

Company Overview

Orexo develops pharmaceuticals and digital therapies designed to address serious diseases, particularly in addiction medicine and mental health. The company combines known drug substances with proprietary delivery technologies to improve absorption, stability and ease of administration.

Its commercial business has historically centered on treatments for opioid use disorder in the United States, while newer programs focus on emergency medicines and reformulated therapies using the company’s AmorphOX drug delivery platform.

Headquarters and Global Presence

Orexo is headquartered in Uppsala, Sweden and conducts research and development from its facilities there.

The company commercializes products directly in the United States and works with partners to distribute medicines in Europe, Asia and other international markets.

Founding and History

Orexo was founded in 1995 and listed on the Stockholm Stock Exchange in 2005.

Early products were developed using sublingual drug-delivery technology, including Abstral for breakthrough cancer pain. The company later expanded into addiction medicine with the launch of ZUBSOLV in the United States in 2013.

More recently Orexo has focused on developing medicines using its AmorphOX powder-based formulation technology, which aims to improve bioavailability and stability for both small molecules and biologics.

Therapy Areas and Focus

Orexo’s development and commercial activities focus on several areas:

Substance use disorders, particularly opioid dependence
Mental health conditions such as depression and alcohol use disorder
Emergency medicines including overdose and anaphylaxis rescue therapies

These areas reflect a strategy centered on addiction medicine, digital therapeutics and rescue medications.

Technology Platforms and Modalities

Orexo’s core technological capability is drug-delivery engineering designed to improve pharmacokinetics and patient convenience.

Key modalities include:

AmorphOX powder-based drug delivery technology
Sublingual drug delivery systems
Intranasal rescue medications
Digital therapeutics based on cognitive behavioral therapy

The AmorphOX platform enables conversion of active ingredients into powder formulations that can be delivered through nasal or oral routes while improving stability and absorption.

Key Products and Pipeline

Selected marketed products include:

ZUBSOLV, a buprenorphine-naloxone combination tablet for opioid use disorder
Abstral, a sublingual fentanyl product for breakthrough cancer pain
Edluar, a sublingual zolpidem formulation for insomnia

Digital therapies include:

Deprexis, a digital cognitive behavioral therapy program for depression
Vorvida, a digital therapy for alcohol management
MODIA, a digital treatment supporting opioid use disorder care

Development programs include:

OX124, a naloxone-based rescue therapy for opioid overdose
OX125, a nalmefene rescue treatment for opioid overdose
OX640, an intranasal epinephrine therapy for anaphylaxis

These programs are built on Orexo’s AmorphOX technology platform.

Key Personnel

Nikolaj Sørensen, President and Chief Executive Officer
Fredrik Jarrsten, Chief Financial Officer
Robert Rönn, Senior Vice President and Head of Research and Development
Edward Kim, Chief Medical Officer
Cecilia Coupland, Senior Vice President and Head of Operations

Strategic Partnerships

Orexo collaborates with pharmaceutical and technology partners for research, development and commercialization.

Notable collaborations include partnerships with GAIA for digital therapeutics targeting substance use disorders and mental health conditions.

FAQ Section

Orexo focuses on improving existing medicines through proprietary drug-delivery technologies. Rather than discovering entirely new active ingredients, the company frequently combines well-characterized compounds with novel formulation approaches to enhance efficacy, stability or ease of administration.

ZUBSOLV is Orexo’s most significant commercial product and forms the core of its U.S. pharmaceutical business. The drug treats opioid use disorder using a sublingual formulation designed to improve bioavailability compared with earlier buprenorphine-based therapies.

AmorphOX is Orexo’s next-generation drug-delivery platform. It converts active pharmaceutical ingredients into powder formulations that improve stability and bioavailability, enabling new delivery routes such as intranasal or oral administration.

The technology is being used to develop rescue medicines for opioid overdose and allergic reactions.

Opioid overdose remains a major public health challenge globally. Orexo’s rescue therapies aim to provide high-dose naloxone or nalmefene in formulations that can be administered quickly and effectively in emergency situations.

The company has commercialized several digital therapy programs based on cognitive behavioral therapy. These software-based treatments are designed to complement pharmaceutical treatments for addiction and mental health disorders.

Orexo operates directly in the United States, where its addiction medicine products are marketed, while working with partners for commercialization in Europe, Japan and other international markets.

Key developments include: